4SC AG Company Profile - Aug 16, 2011 by WrightReports

VIEWS: 17 PAGES: 9

More Info
									Company Fundamentals\Company Profile

   A Wright Investors' Service Research Report:

   4SC Ag
                                                                                       440 Wheelers Farms Road
                                                                                       Milford, CT 06461 U.S.A.


  COMPANY PROFILE
  Figures in Euro

                                 Wright Quality Rating:DANN                                 Key Data

   4SC Ag. 4SC AG is a Germany-based research-oriented drug discovery and                   Ticker:
   development Company. Its research activities center on cancer and autoimmune             VSC
   indications. The Company develops drug candidates until proof-of-concept in order
   to generate value creating partnerships with the pharmaceutical industry in return       2010 Sales:
   for advance and payments as well as royalties. It collaborates with AiCuris in the
                                                                                            989,000
   field of antiviral and antibacterial drug discovery, with ProQinase to identify a new
   generation of protein kinase inhibitors in order to develop anticancer drugs, with and
   ViroLogik in the field of developing, manufacturing and market the compound for viral    Major Industry:
   diseases.                                                                                Drugs, Cosmetics & Health
                                                                                            Care
                       Stock Chart                                   Officers
                                                                    Chairman
                                                               Dr. Joerg Neermann           Sub Industry:
                                                                                            Ethical Drug Manufacturers
                                                          Chairman & Chief Executive
                                                                Dr. Ulrich Dauer     Country:
                                                                                     Germany

                                                                                            Currency:
                                                                                            Euro

                                                                                            Fiscal Year Ends:
                                                                                            December

                                                                                            Employees
                                                                                            94

                                                                                            Exchanges:
                                                                                            FRA
             Stock Price (8/12/2011): 1.58
               Recent stock performance                                                     Share Type:
                  1 Week        5.3%
                                                                                            Stammaktie
                  4 Weeks     -15.5%
                  13 Weeks    -57.3%
                  52 Weeks    -41.5%                                                        Market Capitalization:
                                                                                            66,309,920
                       Earnings / Dividends (as of 6/30/2011)
                       
								
To top